[{"orgOrder":0,"company":"Pantherna Therapeutics","sponsor":"Evaxion Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Pantherna Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pantherna Therapeutics \/ Pantherna Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Pantherna Therapeutics \/ Pantherna Therapeutics"},{"orgOrder":0,"company":"Pantherna Therapeutics","sponsor":"Wacker Chemie AG","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Other Large Molecule","year":"2024","type":"Collaboration","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Pantherna Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pantherna Therapeutics \/ Pantherna Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Pantherna Therapeutics \/ Pantherna Therapeutics"},{"orgOrder":0,"company":"Pantherna Therapeutics","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"GERMANY","productType":"Oligonucleotide","year":"2022","type":"Agreement","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Pantherna Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pantherna Therapeutics \/ Astellas Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Pantherna Therapeutics \/ Astellas Pharma"}]

Find Clinical Drug Pipeline Developments & Deals by Pantherna Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Through the collaboration, company aims to focus on the clinical development of PAN004, which is being evaluated in the preclinical studies for the treatment of acute respiratory distress syndrome.

                          Product Name : Undisclosed

                          Product Type : Other Large Molecule

                          Upfront Cash : Undisclosed

                          July 04, 2024

                          Lead Product(s) : PAN004,Inapplicable

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Preclinical

                          Recipient : Wacker Chemie AG

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : The preclinical data demonstrate that tumor neoantigens identified by Evaxion’s AI platform, PIONEER, drive a strong immune response and lead to complete inhibition of tumor growth in a preclinical model.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          August 02, 2023

                          Lead Product(s) : Undisclosed,Inapplicable

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Recipient : Evaxion Biotech

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Under the new agreement, Pantherna’s mRNA platform and Astellas’ world-class drug discovery capabilities will be combined to promote research on the generation of regenerative medicine programs for new target organ using a direct reprogramming approa...

                          Product Name : PTXmRNAs

                          Product Type : Oligonucleotide

                          Upfront Cash : Undisclosed

                          April 10, 2022

                          Lead Product(s) : PTXmRNAs,Inapplicable

                          Therapeutic Area : Technology

                          Highest Development Status : Discovery

                          Sponsor : Astellas Pharma

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank